LD-2 disclosure · 4th Quarter - Report
ELI LILLY AND COMPANY
Client
- Location
- District of Columbia · United States of America
Registrant
- Description
- pharmaceuticals
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
7 issuesTrade (domestic/foreign)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
LobbyistsDAVID TALBOT · PAUL BURKHEAD · SARAH KYLE · SHAWN O'NEAIL · THOMAS CORDREY ROBERGE jr · SHANNON STEHOUWER · ASKIA SURUMA · JUAN MACHADO · mr FRANK DE LIMA
Covered position (SARAH KYLE): Legislative Asst, Senator Bayh (2007-2011); Legislative Asst, Rep Tim Roemer (2000-2003)
Covered position (THOMAS CORDREY ROBERGE jr): Legislative Counsel (2002-2004 - Senator Peter Fitzgerald)
Covered position (SHANNON STEHOUWER): Staff, Senator John Hoeven (2014-2016); Staff, Rep. Mike Rogers (2010-2014)
Covered position (ASKIA SURUMA): Chief of Staff, Rep. Marc Veasey (2017-2021); Deputy Staff Director, Ways and Means Committee (2007-2014); Deputy Staff Director, House Rules Committee (2001-2007); Legislative Director, Rep. Martin Frost (2000-2001)
Covered position (JUAN MACHADO): Senate Finance Committee; Professional Staff and Senior Health Advisor, Department of Health & Human Services, Health Insurance Specialist
TargetedSENATE · HOUSE OF REPRESENTATIVES · U.S. Trade Representative (USTR) · State, Dept of (DOS)
Health Issues
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)